Home > Dermatology > AAD 2018 > Alopecia Areata > New agents and combination therapy

New agents and combination therapy

Presented By
Prof. Wilma Bergfeld, Cleveland Clinic, USA
AAD 2018
Many new agents in the pipeline Another interesting agent is a novel peptide that inhibits the cytokines IL-2, IL-9, and IL-15 (BNZ-1). Signalling of IL-4, IL-7, and IL-21 are unaffected by this peptide, which preserves immunological function (see Figure). The agent BNZ-1 was effective in a mouse model of immune-mediated hair loss. It led to a reduction of the inflammatory cytokines IL-6, TNF-α and IFNγ and was able to restore hair growth. It proved to be safe in healthy volunteers and a Phase 2 randomised double-blind placebo-controlled dose ranging study in AA is planned in 2018. Figure: Mode of action of the peptide BNZ-1 “Many pharma companies are now interested in hair disorders and in the hair follicle as a model to study inflammatory pathways, so there is more to come in the next years,” said P...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on